Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial

[1]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[2]  C. Benedict,et al.  Erratum: Neurohormonal and clinical responses of high- versus low-dose enalapril therapy in chronic heart failure (Journal of the American College of Cardiology (2002) 39 (70-78)) , 2002 .

[3]  C. Benedict,et al.  Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. , 2002, Journal of the American College of Cardiology.

[4]  D. Chaudhuri,et al.  For personal use. Only reproduce with permission from The Lancet Publishing Group. , 2002 .

[5]  K. Dickstein,et al.  Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. , 2001, The American journal of cardiology.

[6]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[7]  M. Pfeffer,et al.  Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. , 2000, American heart journal.

[8]  W. Bauer,et al.  Effect of quinapril initiated during progressive remodeling in asymptomatic patients with healed myocardial infarction. , 2000, The American journal of cardiology.

[9]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[10]  G. Sanz,et al.  Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. , 2000, European heart journal.

[11]  C. Maynard,et al.  Early use of ACE inhibitors in the treatment of acute myocardial infarction in the United States: experience from the National Registry of Myocardial Infarction 2. National Registry of Myocardial Infarction 2 participants. , 1999, The American journal of cardiology.

[12]  J S Alpert,et al.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.

[13]  K. Dickstein,et al.  Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. , 1999, The American journal of cardiology.

[14]  A. Maggioni.  ACE inhibitor treatment after myocardial infarction , 1999 .

[15]  A. Danser,et al.  Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. , 1998, Circulation.

[16]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[17]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[18]  W. Kiowski,et al.  Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. , 1997, Circulation research.

[19]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[20]  K. Dickstein,et al.  Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. , 1995, Journal of the American College of Cardiology.

[21]  S. Ball,et al.  Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing. , 1995, Journal of the American College of Cardiology.

[22]  C. Sweet,et al.  Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. , 1995, The American journal of cardiology.

[23]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[24]  K. Dickstein,et al.  Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. , 1995, Circulation.

[25]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[26]  E. Fleck,et al.  Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[27]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[28]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[29]  E. Fleck,et al.  Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure , 1993, Circulation.

[30]  P. Mannucci,et al.  Desmopressin and blood loss after cardiac surgery , 1993, The Lancet.

[31]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[32]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[33]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.